xSSATs: a new family of drugs with two major components

Central Component

The central components of the xSSAT family of drugs are FDA approved scaffolds that can vary as needed to achieve desired pharmacokinetic properties and/or cell targeting.

Outer Component

The outer component of the xSSAT family of drugs is part of a drug already approved by the FDA.


BHCRG is the first to combine these two components to make a new drug family. Multiple variations are possible. For example, molecular weights can vary from less than 500 up to 100,000 Daltons.


The xSSATs are new, but the components are well known. This new drug family has novel, unexpected features. xSSATs are being tested for synergistic effects with other anticancer agents.


xSSATs: a new family of drugs with old and new ways of restoring the health of cells, people, and animals.


xSSATs work WITH normal cells, not against them.
(1) Antioxidant
(2) Reducing agent
(3) Redox status modulator


xSSATs work at multiple levels in stressed or diseased cells.
xSSATs restore:
(1) Normal gene expression (specific sites)
(2) Normal protein function (subset of proteins)
(3) Intracellular environment features


xSSATs have a range of activities.
(1) Like natural antioxidants
(2) Like natural reducing agents

New Understanding

xSSATs have known and novel modes of action. We are working to understand better how xSSATs work.


xSSATs: a new family of drugs with old and new applications


xSSATs protect normal cells from outside agents that cause stress, damage, or cell death.


xSSATs inhibit the growth and survival of tested DNA, RNA, and reverse transcribing viruses.


xSSATs stop the growth and/or kill representative lung cancer, prostate cancer, breast cancer, ovarian cancer, and leukemia cells.

New Applications

xSSATs have applications in the treatment of conditions associated with aberrations/defects in cell metabolic networks, cellular microenvironment, and others.


The very latest findings and announcements from BHCRG

April 16, 2020

Dr. Vernon Walker submits new findings.


BHCRG is a 2nd generation company, working on a 2nd generation family of drugs.

Company History: a 2nd generation company

Early 1900s: Dale’s grandfather (AC), won a hotel as payment for poker debts. The hotel was located on Vermont Avenue in Washington, D.C. AC and friends mistakenly renamed it “The Burlington Hotel,” after the capital of Vermont (Montpelier).
– • –
Late 1900s: AC’s children transferred ownership of the hotel to The Burlington HC, Inc.
– • –
2004: hotel property sold.
– • –
2012: Dale and Vernon established a new company (The Burlington HC Research Group, Inc.) based upon new drug discoveries financed by the original company.

Drug family history: a 2nd generation family of drugs

Early 1950s: US military developed and investigated new drugs (called phosphorothioates) as protectants against radiation.
– • –
1950s to present: range of activities of this drug family and/or its active metabolites expanded to include:
– Anti-cancer effect
– Anti-viral effects
– Other beneficial effects
– • –
Problems with drug delivery, metabolism, and toxicity issues for phosphorothioates prevented wide spread use.
– • –
2010 to present: the Walkers discovered new solutions to these problems; this resulted in development of the xSSAT family of drugs.
– • –
2015 to present: the first xSSAT drug was synthesized; testing is ongoing.


Over 100 years of experience

BHCRG was Formed in 2012

It is led by the investigators who made the initial discoveries that led to this new family of drugs. Our team has expertise in diverse areas including chemical carcinogenesis and mutagenesis, molecular biology and pathology, animal drug testing, cellular stress response biology, and toxicology.

Vernon E. Walker, DVM, PhD

Vernon has 35 years experience in the fields of chemical carcinogenesis and mutagenesis, molecular biology, pathology and toxicology. He and Dale were instrumental in the discoveries of the broad spectrum antiviral activity of the aminothiol compound called WR1065, and in the discoveries that led to the development of the xSSAT family of drugs.

Dale M. Walker, DVM

Dale M. Walker has 32 years of experience. She has particular expertise in cellular stress response pathways and their outcomes in mammalian cells, and was instrumental in the development of the “Stress Response Resolution Assay” (SRRR assay). Knowledge obtained from the development of this assay was critical to the discovery and development of the xSSAT family of drugs.

Dr. Mirian Poirier, PhD

Dr. Miriam Poirier, a proposed advisor, is the past head of the Carcinogen-DNA Interactions Section at the NCI and a long-term collaborator who investigated therapeutic activities of WR1065. She continues to provide ongoing advise and support for the advancement of the xSSAT drug family.

call us:


802-777-9394 Vernon E. Walker

802-777-9061 Dale M. Walker

The Burlington HC Research Group, Inc.


10 Marion Way, Jericho VT 05465



Get in touch. Don’t hesitate
to contact us.